Search

Displaying results 2661 - 2670 of 10000 in total
  1. Drug

    Streptococcus pneumoniae type 3 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10321
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR, PNEUMOVAX 23 Injektionslösung in einer Fertigspritze
  2. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.

  3. Drug

    Palifermin

    go.drugbank.com/drugs/DB00039
    ApprovedInvestigational

    It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.[L17933]

  4. Drug

    Mannitol busulfan

    go.drugbank.com/drugs/DB12097
    ApprovedWithdrawn

    Mm has been used in trials studying the treatment of Cocaine Dependence and Diabetes Mellitus, Type 2.

  5. Target

    Cytochrome b-c1 complex subunit 1, mitochondrial

    go.drugbank.com/bio_entities/BE0001005
    TargetHumans

    The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase … Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation.

    Polypeptides: Cytochrome b-c1 complex subunit 1, mitochondrialSynonyms: Ubiquinol-cytochrome-c reductase complex core protein 1, Core protein I
  6. Target

    Holliday junction branch migration complex subunit RuvB

    go.drugbank.com/bio_entities/BE0002792
    TargetThermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)

    The RuvA-RuvB-RuvC complex processes Holliday junction (HJ) DNA during genetic recombination and DNA repair, while the RuvA-RuvB complex plays an important role in the rescue of blocked DNA replication … The RuvB hexamer acts as an ATP-dependent pump, pulling dsDNA into and through the RuvAB complex.

    Polypeptides: Holliday junction branch migration complex subunit RuvB
  7. Target

    Cytochrome b-c1 complex subunit 2, mitochondrial

    go.drugbank.com/bio_entities/BE0003855
    TargetHumans

    The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase … Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation.

    Polypeptides: Cytochrome b-c1 complex subunit 2, mitochondrialSynonyms: Ubiquinol-cytochrome-c reductase complex core protein 2, Core protein II
  8. Target

    Cytochrome b-c1 complex subunit 6, mitochondrial

    go.drugbank.com/bio_entities/BE0003856
    TargetHumans

    The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase … Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation.

    Polypeptides: Cytochrome b-c1 complex subunit 6, mitochondrialSynonyms: Complex III subunit 6, Complex III subunit VIII
  9. Target

    Inner membrane complex sub-compartment protein 3

    go.drugbank.com/bio_entities/BE0009269
    TargetPlasmodium falciparum (isolate 3D7)

    Polypeptides: Inner membrane complex sub-compartment protein 3
  10. Drug

    Revefenacin

    go.drugbank.com/drugs/DB11855
    ApprovedInvestigational

    The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions. … [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]